Plain-English translation of NCT07054801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether lidocaine and methylprednisolone — two medications injected directly into an artery in the brain — can safely and effectively reduce severe headaches caused by subarachnoid hemorrhage (bleeding in the space surrounding the brain). Researchers will give the medication to 25 adult patients during a routine imaging procedure called digital subtraction angiography and then measure how much their headaches improve over the next three months.
Severe headaches are a common and painful problem for patients recovering from subarachnoid hemorrhage, and they can be difficult to treat with standard pain medications alone. This trial is testing whether this new approach of delivering medication directly to the affected blood vessels can provide better relief.
You likely qualify if…
You likely don't qualify if…
If you enroll, the medication will be injected into one of your brain arteries during the digital subtraction angiography procedure you're already scheduled to have — so there's no extra procedure involved. After the injection, you'll be asked to report how your headaches feel at discharge, then return for follow-up visits at days 1–10, weeks 2 and 4, and week 12 to track your pain levels and overall recovery using simple rating scales. You may also be asked about how much pain medication you're taking and your overall neurological function.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States